


Supplemental Figure 1. Kaplan-Meier survival curves for patients receiving sorafenib prescribed by oncologists or GI/hepatologists after propensity matching. No significant differences were identified by Kaplan-Meier or Cox proportional hazard methodologies.



Supplementary Table 1. Baseline Characteristics of Propensity Matched Cohort

Parameter	GI/Hepatology	Oncology	p
General			
N	202	404	
Age (Mean ± SD)	62.3 ± 7.2	62.9 ± 7.8	0.32
Gender (% Female)	2.0	1.0	0.31
Alphafetoprotein (Mean ± SD)	8004 ± 36987	6140 ± 33373	0.51
Race/Ethnicity			
White (%)	57.6	57.6	0.97
Black (%)	33.1	32.4	
Asian (%)	0.3	0.7	
Other (%)	0.3	0.2	
Unknown (%)	8.6	7.6	
Barcelona Liver Cancer Clinic Stage			
A (%)	10.6	10.6	1.0
B (%)	33.1	33.1	
C (%)	51.0	51.0	
D (%)	5.3	5.3	
Comorbidity (Cirrhosis Comorbidity Index)			
0	26.4	25.2	0.04
1+0	35.1	28.1	
1+1	8.6	7.2	
3+0	5.9	7.3	
3+1	15.5	16.2	
5+0	4.9	7.9	
5+1	0.0	0.0	
Model for End Stage Liver Disease (MELD) Score (mean ± sd)			
	15.5 ± 4.9	15.5 ± 4.9	1.0
Child-Turcotte-Pugh Score			
5	28.1	27.8	0.45
6	32.7	27.8	
7	19.5	23.8	
8	10.3	10.3	
9	4.9	6.6	
10	2.6	0.6	
11	1.3	0.3	
12	0.0	0.3	
13	0.3	0.0	
Prescribed full dose (%)			
	66.2	65.2	0.79
Chemoembolization prior to sorafenib (%)			
	43	33.8	0.019
Chemoembolization following sorafenib (%)			
	15.2	7.6	0.003

specialty	1	0	specialty	1	0
circom_0		80	76 age_mean	62.3708609	62.9701987
circom_0_pc	0.26490066	0.25165563	age_sd	7.22823542	7.85642167
circom_1		106	85 meld_mean	15.5033113	15.5033113
circom_1_pc	0.35099338	0.28145695	meld_sd	4.89066393	4.89066393
circom_2		26	22 ctp_mean	6.46357616	6.54304636
circom_2_pc	0.08609272	0.07284768	ctp_sd	1.42951719	1.45695764
circom_3		18	22 afp_mean	8004.49735	6140.04636
circom_3_pc	0.05960265	0.07284768	afp_sd	36987.4988	33373.4508
circom_4		47	49 race_w	174	174
circom_4_pc	0.15562914	0.16225166	race_w_pct	0.57615894	0.57615894
circom_5		10	24 race_b	100	98
circom_5_pc	0.03311258	0.0794702	race_b_pct	0.33112583	0.32450331
circom_6		15	24 race_a	1	2
circom_6_pc	0.04966887	0.0794702	race_a_pct	0.00331126	0.00662252
tace_1_pct	0.43046358	0.33774834	race_o	1	5
tace_2_pct	0.15231788	0.07615894	race_o_pct	0.00331126	0.01655629
male_pct	0.98013245	0.99006623	race_u	26	23
full_dose_pc	0.66225166	0.65231788	race_u_pct	0.08609272	0.07615894
			bclc_a	32	32
			bclc_a_pct	0.10596026	0.10596026
			bclc_b	100	100
			bclc_b_pct	0.33112583	0.33112583
			bclc_c	154	154
			bclc_c_pct	0.50993377	0.50993377
			bclc_d	16	16
			bclc_d_pct	0.05298013	0.05298013
			ctp_5	85	84
			ctp_5_pct	0.28145695	0.2781457
			ctp_6	99	84
			ctp_6_pct	0.32781457	0.2781457
			ctp_7	59	72
			ctp_7_pct	0.19536424	0.2384106
			ctp_8	31	31
			ctp_8_pct	0.10264901	0.10264901
			ctp_9	15	20
			ctp_9_pct	0.04966887	0.06622517
			ctp_10	8	2
			ctp_10_pct	0.02649007	0.00662252
			ctp_11	4	8
			ctp_11_pct	0.01324503	0.02649007
			ctp_12	0	1
			ctp_12_pct	0	0.00331126
			ctp_13	1	0
			ctp_13_pct	0.00331126	0

Supplementary Table 1. Baseline Characteristics of Propensity Matched Cohort

Parameter	GI/Hepatology	Oncology	p
General			
N	202	404	
Age (Mean \pm SD)	62.3 \pm 7.2	62.9 \pm 7.8	0.32
Gender (% Female)	2.0	1.0	0.31
AFP (Mean \pm SD)	8004 \pm 36987	6140 \pm 33373	0.51
Race/Ethnicity			0.97
White (%)	57.6	57.6	
Black (%)	33.1	32.4	
Asian (%)	0.3	0.7	
Other (%)	0.3	0.2	
Unknown (%)	8.6	7.6	
BCLC Stage			1.0
A (%)	10.6	10.6	
B (%)	33.1	33.1	
C (%)	51.0	51.0	
D (%)	5.3	5.3	
Comorbidity (Cirrhosis Comorbidity Index)			0.04
0	26.4	25.2	
1+0	35.1	28.1	
1+1	8.6	7.2	
3+0	5.9	7.3	
3+1	15.5	16.2	
5+0	4.9	7.9	
5+1	0.0	0.0	
MELD Score (mean \pm stdev)	15.5 \pm 4.9	15.5 \pm 4.9	1.0
Child-Turcotte-Pugh Score			0.45
5	28.1	27.8	
6	32.7	27.8	
7	19.5	23.8	
8	10.3	10.3	
9	4.9	6.6	
10	2.6	0.6	
11	1.3	0.3	
12	0.0	0.3	
13	0.3	0.0	
Prescribed full dose (%)	66.2	65.2	0.79
TACE prior to sorafenib (%)	43	33.8	0.019
TACE following sorafenib (%)	15.2	7.6	0.003